NDA 213872 · Bayer Hlthcare
Astepro Allergy
Azelastine Hydrochloride · Nasal
Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 17, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
62
23 Phase 3, 1 recruiting
FAERS reports
1,427
646 serious, 76 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ASTEPRO ALLERGY · AZELASTINE HYDROCHLORIDE 0.2055MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter
- CHILDREN'S ASTEPRO ALLERGY · AZELASTINE HYDROCHLORIDE 0.2055MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Azelastine" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00883168 · 1,791 participants · Start Apr 2009 · Primary completion Jul 2009
Drug: Placebo; azelastineHcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Fountain Valley, California · 45 sites in all
- Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™Pivotal-lookingStatus unknown
Teva Pharmaceuticals USATeva (TEVA)
NCT02249663 · 1,535 participants (planned) · Start Aug 2014 · Primary completion Feb 2015
Drug: Azelastine hydrochloride and Fluticasone propionate; Dymista™ · For: Seasonal Allergic Rhinitis
Sites: Pittsburgh, Pennsylvania
- Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic RhinitisPivotal-lookingCompleted
Padagis LLCIndustry
NCT02230696 · 951 participants · Start Aug 2014 · Primary completion Feb 2015
Drug: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray; Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray and 1 more · For: Seasonal Allergic Rhinitis
Sites: Stockbridge, Georgia; Louisville, Kentucky; Baltimore, Maryland · 30 sites in all
- DYmista NAsal Spray in CHInese PatientsPivotal-lookingCompleted
MEDA Pharma GmbH & Co. KGIndustry
NCT03599791 · 900 participants · Start Jun 29, 2018 · Primary completion Sep 24, 2019
Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT; Azelastine Hydrochloride 0.137 MG/ACTUAT and 1 more · For: Allergic Rhinitis
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 33 sites in all
- Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic RhinitisPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00783432 · 862 participants · Start Jul 2006 · Primary completion Dec 2007
Drug: Astepro Nasal Spray (0.1% azelastine hydrochloride); Astelin Nasal Spray (0.1% azelastine hydrochloride) · For: Chronic Allergic Rhinitis; Nonallergic Rhinitis
Sites: Somerset, New Jersey
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00651118 · 832 participants · Start Mar 2008 · Primary completion Jun 2008
Drug: Placebo; azelastine Hcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Los Angeles, California · 43 sites in all
- A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00740792 · 776 participants · Start Aug 2008 · Primary completion Nov 2008
Drug: azelastine HCl/fluticasone propionate; azelastine Hcl and 2 more · For: Seasonal Allergic Rhinitis
Sites: Scottsdale, Arizona; Encinitas, California; Fountain Valley, California · 39 sites in all
- A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic RhinitisPivotal-lookingCompleted
Meda PharmaceuticalsIndustry
NCT00720382 · 703 participants · Start Mar 2007 · Primary completion Jun 2008
Drug: 0.15% azelastine hydrochloride; Mometasone furoate · For: Perennial Allergic Rhinitis
Sites: Oxford, Alabama; Fountain Valley, California; Huntington Beach, California · 59 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective104
- fatigue100
- headache81
- nausea74
- diarrhoea73
- dizziness60
- dyspnoea54
- pneumonia52
- cough50
- pain50
- vomiting49
- malaise47
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 15 |
| 2008 | 25 |
| 2009 | 22 |
| 2010 | 72 |
| 2011 | 46 |
| 2012 | 40 |
| 2013 | 6 |
| 2014 | 17 |
| 2015 | 62 |
| 2016 | 112 |
| 2017 | 111 |
| 2018 | 140 |
| 2019 | 162 |
| 2020 | 182 |
| 2021 | 133 |
| 2022 | 5 |
| 2023 | 34 |
| 2024 | 5 |
| 2025 | 195 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.
Sousa-Pinto B, Vieira RJ, Bognanni A, et al. · Allergy 2025 · Systematic Review, Network Meta-Analysis
- Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP, Grosheva M, Meiser P, et al. · Sci Rep 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Intranasal spray medications for maintenance therapy of allergic rhinitis.
Berger WE, Meltzer EO · Am J Rhinol Allergy 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.
Meiser P, Flegel M, Holzer F, et al. · Viruses 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, et al. · Drugs 2017 · Meta-Analysis, Systematic Review
Sponsor: Bayer · Also marketed as Children'S Astepro Allergy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.